Public Company Catalysts

Track upcoming catalysts for public biopharma companies: Phase 3 data readouts, FDA decisions, trial initiations, and partnership activity. Identify companies with near-term news that could drive new revenue.

Ask AI about catalysts

Ask a question

Public companies

13Tracked with catalyst data

Phase 3 programs

56 approved

Upcoming catalysts

2213 high-significance

Partnerships

15Active collaborations

Catalyst Timeline

22 events13 high-priority

H1 20264 catalysts

NRIX

📊Data Readout

NX-5948 Phase 1 recommended Phase 2 dose

NX-5948

Ask AI

VRTX

📊Data Readout

Phase 3 DPN pain data

Suzetrigine

Ask AI

BEAM

📊Data Readout

BEAM-101 updated Phase 1/2 data in SCD

BEAM-101

Ask AI

+1 more

H2 20266 catalysts

KYMR

📊Data Readout

BROADEN2 Phase 2b data in Atopic Dermatitis

KT-621

Ask AI

ARVN

📊Data Readout

VERITAC-2 Phase 3 interim analysis

ARV-471

Ask AI

ALNY

📊Data Readout

KARDIA-3 Phase 3 initiation update

Zilebesiran

Ask AI

+3 more

Q1 20263 catalysts

VRTX

🏛️FDA Decision

VX-548/Suzetrigine PDUFA date for acute pain

Suzetrigine

Ask AI

RCKT

🏛️FDA Decision

Kresladi PDUFA date for Fanconi Anemia

Kresladi

Ask AI

MDGL

📊Data Readout

REZDIFFRA launch trajectory and real-world data

Resmetirom

Ask AI

Q2 20267 catalysts

CCCC

📊Data Readout

CFT8919 Phase 1/2 dose expansion data

CFT8919

Ask AI

ALNY

📊Data Readout

HELIOS-B Phase 3 data in ATTR cardiomyopathy

Vutrisiran

Ask AI

SRPT

🏛️FDA Decision

ELEVIDYS full approval decision based on EMBARK data

ELEVIDYS

Ask AI

+4 more

Significance:

High

Medium

Low

Companies with Catalysts

13 companies

KYMRNASDAQ

Kymera Therapeutics

Immunology, Oncology

TPD$2B-4B

Pipeline (4 programs)2b

STAT62bIRAK4Ph 2IRF5Ph 1+1 more

Next catalystHigh

BROADEN2 Phase 2b data in Atopic Dermatitis

📊Data Readout2026-H2

1 high-priority2 partnerships

Ask AI

ARVNNASDAQ

Arvinas

Oncology, Neurology

TPD$3B-5B

Pipeline (3 programs)Ph 3

ERPh 3ARPh 2LRRK2Ph 1

Next catalystHigh

VERITAC-2 Phase 3 interim analysis

📊Data Readout2026-H2

1 high-priority1 partnerships

Ask AI

CCCCNASDAQ

C4 Therapeutics

Oncology

TPD$500M-1B

Pipeline (3 programs)1/2

EGFR1/2BRAFPh 1IKZF131/2

Next catalystHigh

CFT8919 Phase 1/2 dose expansion data

📊Data Readout2026-Q2

1 high-priority2 partnerships

Ask AI

NRIXNASDAQ

Nurix Therapeutics

Oncology, Inflammation

TPD$500M-1B

Pipeline (2 programs)Ph 1

BTKPh 1BTKPh 1

Next catalystHigh

NX-5948 Phase 1 recommended Phase 2 dose

📊Data Readout2026-H1

1 high-priority2 partnerships

Ask AI

GLUENASDAQ

Monte Rosa Therapeutics

Oncology

TPD$200M-500M

Pipeline (2 programs)Ph 1

GSPT1Ph 1IKZF2Ph 1

Next catalystMedium

MRT-2359 Phase 1 dose escalation data

📊Data Readout2026-Q2

1 partnerships

Ask AI

ALNYNASDAQ

Alnylam Pharmaceuticals

RNAi Therapeutics

RNA$25B-35B

Pipeline (3 programs)Appvd

TTRAppvdTTRAppvdAGTPh 2

Next catalystHigh

HELIOS-B Phase 3 data in ATTR cardiomyopathy

📊Data Readout2026-Q2

1 high-priority2 partnerships

Ask AI

VRTXNASDAQ

Vertex Pharmaceuticals

CF, Pain, Gene Editing

Biotech$100B-120B

Pipeline (3 programs)Appvd

BCL11A (gene editing)AppvdNaV1.8Ph 3NaV1.8Ph 3

Next catalystHigh

VX-548/Suzetrigine PDUFA date for acute pain

🏛️FDA Decision2026-Q1

2 high-priority1 partnerships

Ask AI

SRPTNASDAQ

Sarepta Therapeutics

Duchenne MD, Gene Therapy

Gene Therapy$10B-15B

Pipeline (2 programs)Appvd

Micro-dystrophin (gene therapy)AppvdMicro-dystrophinPh 3

Next catalystHigh

ELEVIDYS full approval decision based on EMBARK data

🏛️FDA Decision2026-Q2

1 high-priority1 partnerships

Ask AI

BPMCNASDAQ

Blueprint Medicines

Precision Oncology, Mast Cell

Biotech$5B-8B

Pipeline (3 programs)Appvd

KIT D816VAppvdKIT D816V (next-gen)Ph 2CDK2Ph 1

Next catalystHigh

HARBOR Phase 2 elenestinib data in ISM

📊Data Readout2026-Q2

1 high-priority

Ask AI

RCKTNASDAQ

Rocket Pharmaceuticals

Gene Therapy, Rare Disease

Gene Therapy$1B-3B

Pipeline (3 programs)Ph 3

FANCA (gene therapy)Ph 3ARSA (gene therapy)Ph 2GAA (AAV gene therapy)Ph 1

Next catalystHigh

Kresladi PDUFA date for Fanconi Anemia

🏛️FDA Decision2026-Q1

1 high-priority

Ask AI

RVMDNASDAQ

Revolution Medicines

RAS Oncology

Biotech$8B-12B

Pipeline (3 programs)Ph 2

RAS(ON) MultiPh 2RAS(ON) G12C1/2RAS(ON) G12DPh 1

Next catalystHigh

RMC-6236 Phase 2 expansion data in NSCLC and PDAC

📊Data Readout2026-Q2

1 high-priority1 partnerships

Ask AI

BEAMNASDAQ

Beam Therapeutics

Base Editing

Gene Therapy$2B-4B

Pipeline (2 programs)1/2

HBG1/2 (base editing)1/2CD7/TRAC (base editing)1/2

Next catalystHigh

BEAM-101 updated Phase 1/2 data in SCD

📊Data Readout2026-H1

1 high-priority2 partnerships

Ask AI

MDGLNASDAQ

Madrigal Pharmaceuticals

NASH/MASH

Biotech$5B-8B

Pipeline (1 programs)Appvd

THR-betaAppvd

Next catalystHigh

REZDIFFRA launch trajectory and real-world data

📊Data Readout2026-Q1

1 high-priority

Ask AI

Data sources:Company IRClinicalTrials.govSEC EDGARPress releases

Catalyst dates are estimates based on company guidance and may change. This information is for research purposes only and does not constitute investment advice. Always verify with primary sources and conduct your own due diligence before making investment decisions.